Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Beijing, China, December 29, 2025– Gan&Lee Pharmaceuticals (hereinafter referred to as "Gan&Lee," stock code: 603087.SH) officially announced the signing of an exclusive licensing and supply agreement with Lupin Ltd. (hereinafter referred to as "Lupin"), a global leading pharmaceutical company. The two parties will engage in an in-depth strategic cooperation focusing on Gan&Lee's self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) bi-weekly formulation – Bofanglutide (research code: GZR18).
Based on this collaboration, Gan&Lee Pharmaceuticals has granted Lupin the exclusive development and commercialization rights for Boglyron (Bofanecuglutide) Injection in India. This partnership not only marks Gan&Lee Pharmaceuticals' initiation of the commercial layout for Boglyron in the Indian market but also represents an important step in deepening the company's self-innovated R&D achievements within the Asian market. According to the cooperation plan, Lupin will conduct specific clinical studies in India to provide robust data support for Boglyron’s local market registration. Leveraging Lupin’s well-established commercial system in India, Boglyron Injection is expected to capitalize on its unique "bi-weekly dosing" advantage to become the first bi-weekly GLP-1RA product launched in the region, seizing a first-mover market advantage.
As the global burden of metabolic diseases continues to increase, GLP-1 drugs are ushering in vast market development opportunities. According to data from Grand View Research, the global market size for GLP-1 weight-loss drugs is projected to grow more than threefold over the next six years — surging from US$13.84 billion in 2024 to US$48.84 billion by 2030.Compound Annual Growth Rate (CAGR)Up to 18.5%1Among them, the growth potential of the Indian market is particularly prominent: it is expected that the revenue of the Indian GLP-1RA market will reach 120 million US dollars in 2025, and is expected to climb to 730 million US dollars by 2033. The compound annual growth rate during the period from 2026 to 2033 is expected to be as high as 19.1%, leading among major global markets in terms of growth rate.2。
Gan&Lee Pharmaceuticals EVP & CCO Du Kai and Key Account Director Dr. Dhaval Soneji jointly stated: "This collaboration with Lupin marks another significant milestone in the company’s globalization strategy, following the exclusive agreement for Boguan Glucagon in Latin America signed in November. Moving forward, the company will continue to deepen its global collaboration network, accelerate the worldwide transformation and implementation of innovative achievements, and provide higher-quality treatment options for patients with metabolic diseases globally, further showcasing the value of China's biopharmaceutical innovation on the international stage."
Lupin's Managing Director, Nilesh Gupta, pointed out: "Metabolic diseases such as obesity are significant global health challenges. This collaboration with Gan&Lee Pharmaceuticals reflects our shared goal of providing innovative therapies to patients and will enhance India's management of metabolic diseases."”
Lupin's India Region Formulations President, Rajeev Sibal, added: "The bi-weekly dosing regimen of the Boguan Glucagon-like Peptide Injection significantly enhances patient convenience and adherence. This collaboration will enrich Lupin's innovative product portfolio and advance systematic treatment management for chronic metabolic diseases in India."”
Lupin Ltd., headquartered in Mumbai, India, is a global pharmaceutical giant with products marketed in over 100 countries worldwide. The company has a strong presence in the pharmaceutical industry, with operations spanning branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs). Backed by its solid reputation among healthcare professionals and consumers globally, Lupin Ltd. holds leading positions in key markets such as India and the United States, with significant influence across multiple therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. With 15 state-of-the-art manufacturing facilities and seven research and development centers globally, Lupin Ltd. employs over 24,000 professionals. Through its subsidiaries—Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions—the company is committed to continuously improving patient health outcomes.
1. Grand View Research. (2025). GLP-1 agonists weight loss drugs market size report, 2030. https://www.grandviewresearch.com/industry-analysis/glp-1-agonists-weight-loss-drugs-market-report
2. Grand View Research. (2025). India Glp-1 Receptor Agonist Market Size & Outlook. https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/india
Copyright Statement: This article is reproduced fromGan&Lee Pharmaceuticals, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
